|
KMID : 1218220110030020058
|
|
Korean Journal of Pediatric Urology
2011 Volume.3 No. 2 p.58 ~ p.62
|
|
|
Efficacy and Tolerability of Solifenacin as a Primary Drug Therapy for Overactive Bladder in Children
|
|
Choo Min-Soo
Lee Jung-Hoon
Park Kwan-Jin
|
|
|
Abstract
|
|
|
Purpose: To evaluate the efficacy and tolerability of solifenacin in children with an overactive bladder as primary pharmacotherapy.
Materials and Methods: 188 children with suspected evidence of overactive bladder, who were treated with solifenacin between Feb. 2010 and Oct. 2011, were retrospectively reviewed. Excluding neurogenic causes and cases with concomitant other pharmacologic therapies, the data of 48 patients were analyzed. The efficacy was assessed by subjective symptomatic relief and parameters of the objective voiding diaries based on the recommendation from International Children’s Continence Society classification. The tolerability of drug was examined by patients report, ultrasound and KUB. Both efficacy and tolerability were assessed regularly at 6, 12 and 24 weeks of follow-up.
Results: Included in our analysis were 23 girls and 25 boys with a mean age of 9.8 years (4-25). Most patients were initially treated with 5mg of solifenacin and mean treatment duration was 119 days (14-358). Symptomatic improvement was observed in 26 (54%) patients, and 4 of them showed complete resolution of symptoms. It was not until 56 (median, 7-295) days of medication that patients started to perceive significant improvement. Within 3 months of medication, in 73% of patients efficacy was demonstrated as has been shown in other anticholinergic trials. Constipation (n=7), dry mouth (n=1) and blurred vision (n=1) was recorded as an adverse reaction related to solifenacin treatment. Most of them were mild and only 2 patients discontinued their treatment due to adverse events.
Conclusions: Solifenacin was well tolerated and showed comparable efficacy to other anticholinergics in children as primary pharmacological therapy for overactive bladder. In most patients, the effects occurred within 3 months.
|
|
|
KEYWORD
|
|
|
Overactive bladder, Cholinergic antagonist
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|